MESA LABORATORIES INC /CO/
MLABNasdaq
$97.94
↓ -1.5%Jul 17 close · end-of-day
Price
1Y↑ +24.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$545.0M
Enterprise Value
$585.6M
P/E
80.9
P/S
2.2
P/B
2.9
EV/EBITDA
24.6
PEG
0.9
FCF Yield
7.3%
Dividend Yield
0.7%
Revenue (TTM)
$249.1M
Net Income (TTM)
$6.7M
Free Cash Flow (TTM)
$39.6M
Gross Margin
63.5%
Operating Margin
7.4%
Net Margin
2.7%
ROE
3.6%
ROIC
4.6%
Debt / Equity
0.4
Net Cash
-$40.6M
Return 1Y
+31.4%
Company profile
Mesa Laboratories, Inc. designs, manufactures, and markets quality control instruments and disposable products. The Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.
- CEO
- Gary M. Owens
- Sector
- Manufacturing
- Industry
- Measuring And Control Equipment
- Employees
- 680
- Headquarters
- Colorado
- Website
- mesalabs.com
Management & directors
- Archbold Brian DavidSVP Operations
- Crennen Lyndsey ElizabethCAO
- Sakys JohnCFO
- Owens Gary MPresident and CEO
Roles derived from SEC Form 4 filings.
Earnings
MLAB Q4 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$63.7M↑ +2.6%
Diluted EPS-$0.74↓ -43.1%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
| Revenue | $133.9M | $184.3M | $219.1M | $216.2M | $241.0M | $249.1M |
| Gross profit | $87.0M | $109.1M | $133.7M | $133.3M | $150.9M | $158.3M |
| Operating income | $12.4M | $4.7M | $3.3M | -$272.1M | $16.3M | $18.5M |
| Net income | $3.3M | $1.9M | $930,000.00 | -$254.2M | -$2.0M | $6.7M |
| Diluted EPS | $0.64 | $0.35 | $0.17 | -$47.20 | -$0.36 | $1.21 |
| Operating cash flow | $37.1M | $39.2M | $28.0M | $44.1M | $46.8M | $42.8M |
| Free cash flow | $35.1M | $34.8M | $23.4M | $41.6M | $42.6M | $39.6M |
| Gross margin | 65.0% | 59.2% | 61.0% | 61.6% | 62.6% | 63.5% |
| Operating margin | 9.2% | 2.6% | 1.5% | -125.9% | 6.8% | 7.4% |
| Net margin | 2.4% | 1.0% | 0.4% | -117.6% | -0.8% | 2.7% |
| Line item | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '25 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $58.2M | $57.8M | $62.8M | $62.1M | $59.5M | $60.7M | $65.1M | $63.7M |
| Gross profit | $37.2M | $35.5M | $39.8M | $38.4M | $36.9M | $37.3M | $41.8M | $42.2M |
| Operating income | $5.6M | $3.5M | $5.8M | $1.5M | $3.1M | $4.7M | $8.0M | $2.7M |
| Net income | $3.4M | $3.4M | -$1.7M | -$7.1M | $4.7M | $2.5M | $3.6M | -$4.1M |
| Diluted EPS | $0.62 | $0.63 | -$0.31 | -$1.30 | $0.85 | $0.45 | $0.65 | -$0.74 |
| Operating cash flow | $10.7M | $5.3M | $18.1M | $12.7M | $1.9M | $8.2M | $18.8M | $14.0M |
| Free cash flow | $9.9M | $3.5M | $17.3M | $11.9M | $884,000.00 | $7.1M | $18.0M | $13.5M |
| Gross margin | 64.0% | 61.3% | 63.3% | 61.8% | 62.0% | 61.5% | 64.2% | 66.2% |
| Operating margin | 9.6% | 6.1% | 9.2% | 2.4% | 5.1% | 7.8% | 12.2% | 4.3% |
| Net margin | 5.8% | 5.9% | -2.7% | -11.4% | 8.0% | 4.1% | 5.6% | -6.5% |
Company news
Jun 4, 2026
May 27, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-22 | Sakys John· CFO | Sale | 2,827 | $89.50 | $253,022.15 | filing |
| 2026-06-22 | Archbold Brian David· SVP Operations | Sale | 2,516 | $89.50 | $225,187.03 | filing |
| 2026-06-22 | Crennen Lyndsey Elizabeth· CAO | Sale | 442 | $89.50 | $39,559.88 | filing |
| 2026-06-18 | Sakys John· CFO | Option exercise | 2,756 | $95.10 | $262,095.60 | filing |
| 2026-06-18 | Archbold Brian David· SVP Operations | Option exercise | 2,480 | $95.10 | $235,848.00 | filing |
| 2026-06-18 | Sakys John· CFO | Award | 2,282 | $95.10 | $217,018.20 | filing |
| 2026-06-18 | Archbold Brian David· SVP Operations | Award | 1,859 | $95.10 | $176,790.90 | filing |
| 2026-06-18 | Sakys John· CFO | Option exercise | 1,036 | $95.10 | $98,523.60 | filing |
| 2026-06-18 | Archbold Brian David· SVP Operations | Option exercise | 844 | $95.10 | $80,264.40 | filing |
| 2026-06-18 | Crennen Lyndsey Elizabeth· CAO | Option exercise | 368 | $95.10 | $34,996.80 | filing |
| 2026-06-18 | Crennen Lyndsey Elizabeth· CAO | Award | 263 | $95.10 | $25,011.30 | filing |
| 2026-06-18 | Crennen Lyndsey Elizabeth· CAO | Option exercise | 233 | $95.10 | $22,158.30 | filing |
| 2026-06-18 | Crennen Lyndsey Elizabeth· CAO | Option exercise | 125 | $95.10 | $11,887.50 | filing |
| 2026-06-16 | Sakys John· CFO | Sale | 1,223 | $101.27 | $123,849.54 | filing |
| 2026-06-16 | Archbold Brian David· SVP Operations | Sale | 1,151 | $101.27 | $116,558.32 | filing |
| 2026-06-16 | Crennen Lyndsey Elizabeth· CAO | Sale | 118 | $101.27 | $11,949.51 | filing |
| 2026-06-15 | Sakys John· CFO | Option exercise | 2,717 | $104.08 | $282,785.36 | filing |
| 2026-06-15 | Archbold Brian David· SVP Operations | Option exercise | 2,454 | $104.08 | $255,412.32 | filing |
| 2026-03-10 | Ladiwala Shiraz Shabanali | Buy | 3,500 | $72.23 | $252,805.00 | filing |
| 2026-03-10 | Tripeny R Tony | Buy | 1,315 | $76.00 | $99,940.00 | filing |
| 2026-03-10 | Capone Mark Christopher | Buy | 1,301 | $76.35 | $99,331.35 | filing |
| 2025-12-02 | Sullivan John James | Gift | 2,000 | $0.00 | $0.00 | filing |
| 2025-10-27 | Owens Gary M· President and CEO | Option exercise | 11,558 | $0.00 | $0.00 | filing |
| 2025-08-15 | Ladiwala Shiraz Shabanali | Option exercise | 1,949 | $0.00 | $0.00 | filing |
| 2025-08-15 | Sullivan John James | Option exercise | 1,404 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.